Education
About Us
Working with TipRanks
Follow Us
Cigna Corp (CI)
NYSE:CI
Top Page
Cigna
(NYSE:CI)69Neutral
Positive Factors
Earnings Recovery
Analyst estimates 2026 adjusted pretax income to grow by 10% year-over-year, indicating potential recovery.
Specialty Growth
The strength in specialty trends is likely to represent upside to the estimates.
Negative Factors
Stop Loss Business
A meaningful shortfall in CI's stop loss business drove pressure in the shares.
Cigna (CI) vs. S&P 500 (SPY)
Market Cap
$85.25B
Dividend Yield1.81%
Average Volume (3M)1.97M
Price to Earnings (P/E)25.7
Beta (1Y)0.32
Revenue Growth25.19%
EPS GrowthN/A
CountryUS
Employees72,500
SectorHealthcare
Sector Strength74
IndustryMedical Service Plans
Share Statistics
EPS (TTM)12.23
Shares Outstanding273,678,470
10 Day Avg. Volume2,000,122
30 Day Avg. Volume1,973,786
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.35
Price to Cash Flow (P/CF)4.10
P/FCF Ratio3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$365.39Price Target Upside17.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Cigna Business Overview & Revenue Model
Company DescriptionFounded in 1792, Cigna Corporation is a Connecticut-based global health services company, which provides insurance and related products and services. It operates through the following segments: Health Services, Integrated Medical, International Markets, and Group Disability and Other.
How the Company Makes MoneyCigna makes money primarily through the sale of insurance products and health services. Its key revenue streams include premiums collected from policyholders for medical, dental, disability, life, and accident insurance coverage. Additional revenue is generated through fees for various health services, such as pharmacy benefit management services, and administrative fees for managing medical plans. Cigna also earns income from its international operations, offering health coverage and services in various countries. Significant partnerships with healthcare providers, employers, and government programs contribute to its earnings by expanding its customer base and enhancing service offerings. Investment income from its portfolio of financial assets provides an additional source of revenue.
Cigna Financial Statement Overview
Summary
Cigna shows a strong revenue growth trajectory with stable operational performance. Despite low net profit margins, the company maintains a healthy cash flow and manageable leverage. However, the low return on equity and net income indicate potential areas for improvement in profitability. Overall, the financial statements reflect a well-managed company with opportunities for enhancement in profit margins.Income Statement
Cigna has shown consistent revenue growth over the years, with a notable increase from $195.2 billion in 2023 to $247.1 billion in 2024. However, net profit margin is low at 0.14% for 2024, impacted by a significant drop in net income. EBIT margin remains stable at 3.81% in 2024, with EBITDA margin at 3.81% as well, indicating consistent operational performance despite the challenges.75
Positive
Balance Sheet
The company's debt-to-equity ratio is around 0.78, showing a moderate level of leverage. The equity ratio stands at 26.32%, reflecting a stable financial position. Return on equity is low at 0.84% for 2024, suggesting limited returns for shareholders. The balance sheet reflects a stable asset base with manageable debt levels.70
Positive
Cash Flow
Operating cash flow remains strong at $10.4 billion in 2024, although slightly down from the previous year. Free cash flow is robust at $8.96 billion, indicating strong cash generation capabilities. The free cash flow to net income ratio is high, showcasing effective cash management despite lower net income.80
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 247.12B | 195.19B | 180.64B | 174.27B | 160.58B | Gross Profit |
| 247.12B | 0.00 | 148.44B | 140.71B | 127.87B | EBIT |
| 9.42B | 8.54B | 9.50B | 8.35B | 8.71B | EBITDA |
| 9.42B | 9.57B | 12.55B | 10.91B | 15.11B | Net Income Common Stockholders |
| 344.00M | 5.16B | 6.70B | 5.37B | 8.46B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 7.55B | 8.75B | 6.83B | 6.00B | 11.51B | Total Assets |
| 155.88B | 152.76B | 143.93B | 154.89B | 155.45B | Total Debt |
| 31.97B | 30.93B | 31.09B | 33.67B | 32.92B | Net Debt |
| 24.42B | 23.11B | 25.17B | 28.59B | 22.74B | Total Liabilities |
| 114.64B | 106.41B | 98.98B | 107.70B | 105.06B | Stockholders Equity |
| 41.03B | 46.22B | 44.87B | 47.11B | 50.32B |
| Cash Flow | Free Cash Flow | |||
| 8.96B | 10.24B | 7.36B | 6.04B | 9.26B | Operating Cash Flow |
| 10.36B | 11.81B | 8.66B | 7.19B | 10.35B | Investing Cash Flow |
| -2.10B | -5.17B | 3.10B | -3.61B | 2.98B | Financing Cash Flow |
| -7.65B | -4.29B | -11.24B | -8.21B | -8.53B |
Cigna Technical Analysis
Positive
309.83
Price Trends
289.57
Positive
304.67
Positive
321.14
Negative
Market Momentum
4.85
Negative
60.25
Neutral
67.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CI, the sentiment is Positive. The current price of 309.83 is above the 20-day moving average (MA) of 298.30, above the 50-day MA of 289.57, and below the 200-day MA of 321.14, indicating a neutral trend. The MACD of 4.85 indicates Negative momentum. The RSI at 60.25 is Neutral, neither overbought nor oversold. The STOCH value of 67.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CI.
Cigna Risk Analysis
Cigna disclosed 28 risk factors in its most recent earnings report. Cigna reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cigna Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $80.67B | 29.50 | 51.23% | 0.41% | 14.29% | -1.20% | |
76 Outperform | $80.96B | 17.56 | 6.07% | 4.10% | 4.02% | -43.51% | |
75 Outperform | $28.71B | 9.26 | 12.51% | ― | 5.89% | 27.09% | |
69 Neutral | $85.25B | 25.69 | 0.84% | 1.81% | 25.19% | ― | |
67 Neutral | $31.70B | 26.31 | 7.37% | 1.35% | 10.70% | -49.85% | |
65 Neutral | $434.13B | 30.61 | 14.66% | 1.75% | 8.35% | -35.14% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% |
* Healthcare Sector Average
Performance Comparison
CI
Cigna
309.83
-24.25
-7.26%
CNC
Centene
59.00
-18.59
-23.96%
CVS
CVS Health
65.95
-5.15
-7.24%
HUM
Humana
262.12
-73.17
-21.82%
MCK
McKesson
639.62
116.98
22.38%
UNH
UnitedHealth
475.98
10.67
2.29%
Cigna Earnings Call Summary
Earnings Call Date: Jan 30, 2025 | % Change Since: 2.65% | Next Earnings Date: May 2, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture. While there were significant achievements in terms of revenue growth, shareholder returns, and strong performance in Evernorth, there were notable challenges in the stop loss segment that impacted overall earnings. The company's proactive measures to address these issues and its strong financial position indicate a balanced outlook.Highlights
Full-Year Revenue Growth
Cigna delivered full-year revenue growth of 27% to approximately $247 billion.
Record Shareholder Returns
The company returned $8.6 billion to shareholders through dividends and share repurchase, with an 8% increase in the quarterly dividend to $1.51 per share.
Strong Performance in Evernorth
Evernorth's specialty and care services segment showed strong results, with adjusted revenues growing 33% to $53.7 billion and pre-tax adjusted earnings growing 14% to $2.1 billion.
Biosimilar Adoption Success
Biosimilar use for eligible Humira scripts reached nearly 50% by year-end 2024, and plans to offer an interchangeable Stelara Biosimilar with $0 cost to patients were announced.
Strong Cash Flow and Capital Deployment
Cigna delivered $10.4 billion of cash flow from operations in 2024 and expects to deliver approximately $10 billion in 2025.
Lowlights
Stop Loss Medical Costs Pressure
Higher than expected medical costs in stop loss products resulted in a full-year medical care ratio of 83.2%, which was above the guidance range.
Underperformance in Cigna Healthcare Segment
Cigna Healthcare's fourth quarter earnings were below expectations due to elevated medical costs in stop loss products, resulting in a medical care ratio of 87.9%.
Shortfall in Adjusted Earnings Per Share
Adjusted earnings per share for the full year were $27.33, representing an increase of 9% year-over-year but falling short of expectations.
Company Guidance
During the call, the Cigna Group provided detailed guidance on several financial metrics, reflecting their strategic direction and financial health. For the full-year 2024, Cigna reported a 27% growth in revenue, reaching approximately $247 billion, and adjusted earnings per share (EPS) of $27.33, which marked a 9% increase year-over-year but fell short of expectations. They returned $8.6 billion to shareholders through dividends and share repurchases, with an 8% increase in quarterly dividends to $1.51 per share. Looking ahead to 2025, Cigna anticipates EPS of at least $29.50, driven by revenue projections of $252 billion and adjusted income from operations of $7.9 billion. The company expects to maintain a strong capital position, projecting $10 billion in operating cash flow and planning significant share repurchases, supported by an increased authorization of $10.3 billion. Despite the short-term pressures, particularly in their stop loss products, they remain confident in achieving long-term growth targets of 10% to 14%, leveraging their differentiated capabilities and business portfolio.Cigna Corporate Events
Business Operations and StrategyFinancial Disclosures
Cigna Reaffirms 2025 Income Projection Amid Challenges
Positive
Mar 3, 2025
The Cigna Group announced its intention to reaffirm its projected full-year 2025 consolidated adjusted income from operations of at least $29.50 per share during upcoming meetings with investors and analysts. This reaffirmation highlights the company’s confidence in its financial performance and strategic initiatives, despite the challenges and uncertainties in the healthcare sector.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.